Bausch to Stop Glaucoma Eye Drop Development After Trial Miss

Bausch + Lomb drug fails in glaucoma, but a new use beckons

Bausch + Lomb drug fails in glaucoma, but a new use beckons Phil.Taylor Fri, 10/07/2026

Bausch to stop glaucoma eye drop development after trial miss - Regional Media News

July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study. The company said it will discontinue development of the eye drops for glaucoma-related vision improvement. Here are further details: - • Bausch acquired the eye drop BL1107 through a buyout of Whitecap Biosciences last year. • U.S.-listed shares of the compa…

Bausch + Lomb abandons glaucoma drops after phase 2 failure

Bausch + Lomb ends BL1107 glaucoma eye drop after phase 2 miss, but continues as sustained-release implant for geographic atrophy with 2028 trials. Read more now.

Bausch to stop glaucoma eye drop development after trial miss

July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a ‌mid-stage trial of replicating visual function improvements observed in a smaller study. The company said it will discontinue ‌development ​of the e...

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

VAUGHAN, Ontario -- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totali…

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective ...